Market
Story
Ro Partners with Eli Lilly to Offer Lower-Priced Zepbound Vials with Cash-Pay Option
Dec 11, 2024, 01:42 PM
Telehealth company Ro has partnered with pharmaceutical giant Eli Lilly to expand access to Zepbound, a weight-loss drug containing tirzepatide. The partnership will enable Ro to offer lower-priced, single-dose vials of Zepbound through LillyDirect, Eli Lilly's self-pay pharmacy channel. Ro patients with on-label prescriptions will have access to the drug starting Wednesday, with a cash-pay option available. This collaboration comes amid ongoing shortages of semaglutide-based drugs, such as Ozempic, and questions about the future of compounded GLP-1 treatments. The announcement has impacted the stock performance of Hims & Hers Health, Inc. (HIMS), a company that sells compounded semaglutide, with shares falling 3.8% pre-market.
View original story
Similar markets
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
More than $3 billion • 25%
$2 billion to $3 billion • 25%
Stock price increases by more than 15% • 25%
Stock price increases by less than 5% • 25%
Stock price increases by 5% to 10% • 25%
Stock price increases by 10% to 15% • 25%
Yes • 50%
No • 50%
More than 300,000 • 25%
100,000 to 200,000 • 25%
Less than 100,000 • 25%
200,000 to 300,000 • 25%
Yes • 50%
No • 50%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
1-2 new partnerships • 25%
5 or more new partnerships • 25%
3-4 new partnerships • 25%
0 new partnerships • 25%
76-100% reduction • 25%
0-25% reduction • 25%
26-50% reduction • 25%
51-75% reduction • 25%